Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Lumos Diagnostics (ASX:LDX), a point-of-care diagnostics company, has been sold down despite achieving a key US regulatory milestone. In April 2026, Ryder Capital said Lumos was again its key detractor, continuing to fall despite being well capitalised and ready to accelerate commercially after receiving an FDA CLIA waiver for its FebriDx test. SG Hiscock believes Lumos remains materially undervalued, with the waiver allowing FebriDx to be used in a much broader range of US clinical settings. Lumos Diagnostics operates in the Healthcare sector within the Healthcare Equipment and Supplies industry, and Thesis Tracker has captured 8 comments from 2 fund managers, Ryder Capital and SG Hiscock. Founded in 2015 and headquartered in Melbourne, Lumos develops and manufactures rapid point-of-care diagnostic tests, led by FebriDx, which helps clinicians distinguish bacterial from viral respiratory infections to guide antibiotic prescribing, and provides contract development services to diagnostic partners.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Ryder Capital, SG Hiscock & Company and Acorn Capital have invested in Lumos Diagnostics Holdings Ltd (ASX:LDX).
Ryder and SG Hiscock highlight the FDA CLIA waiver for FebriDx, which opens a much larger US market of doctors' offices and urgent care clinics, and a well-capitalised balance sheet after a raise.
Ryder notes the shares were aggressively sold off after the capital raise and continued falling, and commercial success depends on US adoption of FebriDx.
Lumos Diagnostics Holdings Ltd is a point-of-care diagnostics company founded in 2015. Headquartered in Melbourne, Australia, the firm develops and manufactures diagnostic solutions to assist healthcare professionals in diagnosing and managing medical conditions. Lumos Diagnostics operates across two primary geographical segments: the United States and Australia. The company manages a comprehensive portfolio of diagnostics products and services designed to improve clinical outcomes and diagnostic accuracy for medical providers.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.